Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01378377 · ClinicalTrials.gov registry record · Phase 1
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
A Phase 1 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01378377 is a Phase 1 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 33 participants.
The verdict
NCT01378377, a Phase 1 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The research trial is testing the experimental drug pimasertib and the drug Torisel, given together, in the treatment of advanced solid tumors. The primary purpose of the study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of the drug combination.
Interventions
- DRUG Temsirolimus
- DRUG Pimasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-05-27 |
| Est. Completion | 2012-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01378377
The ClinicalTrials.gov registry entry for NCT01378377 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temsirolimus is the first listed.
NCT01378377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01378377 about?
NCT01378377 is a clinical study titled "Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus". The research trial is testing the experimental drug pimasertib and the drug Torisel, given together, in the treatment of advanced solid tumors. The primary purpose of the study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of the drug combination.
What is the current status of trial NCT01378377?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2011-05-27. Estimated completion is 2012-02-23.
What interventions are being tested in trial NCT01378377?
The interventions under investigation include: Temsirolimus (DRUG), Pimasertib (DRUG).
Who is sponsoring clinical trial NCT01378377?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.